Synopsis
Match systemic breast-cancer treatment to receptor biology and recurrence risk, understand treatment sequence and monitoring, and interpret genomic tools without replacing clinical judgement.
- Endocrine therapy treats hormone-receptor-driven disease by blocking the oestrogen receptor, suppressing gonadal function or reducing oestrogen synthesis; selection depends on reproductive organs and menopausal status.
- Cytotoxic chemotherapy is chosen from absolute recurrence benefit, stage, grade, phenotype, fitness and patient preference; it treats systemic risk but carries marrow, infection, neuropathy, cardiac, fertility and other toxicities.
- HER2-positive cancer requires a confirmed HER2 result and may receive HER2-directed treatment before or after surgery; baseline and interval cardiac assessment follows the selected regimen.
Reasoning priorities
Identify endocrine and HER2 targets before the initial systemic treatment decision.
Request simultaneously on invasive tumour. Resolve equivocal HER2 results through the validated laboratory algorithm before prescribing targeted treatment.
Worked reasoning
A postmenopausal patient has a small ER-positive, HER2-negative, node-negative grade 2 cancer and uncertainty about chemotherapy benefit.
- In this illustrative case, final excision confirms a small ER-positive, HER2-negative, node-negative grade 2 tumour with clear margins. The clinic documents an intermediate distant-recurrence risk using a validated assessment; chemotherapy remains a meaningful unresolved choice.
- The postmenopausal patient says that an expression-test result would help her decide about chemotherapy. The service confirms the HTG719 node-negative evidence-generation requirements, intended use, access conditions and laboratory quality arrangements before ordering the agreed test. Her ER-positive tumour is within the selected test’s receptor scope.
- The report places the tumour in a lower-risk expression category within the test’s intended setting. The oncologist interprets that finding beside tumour size, grade, nodal status, age and the patient’s priorities, rather than treating a score as an automatic instruction.
- After discussing the expected benefits and adverse effects of the available options, the patient chooses the recommended endocrine treatment without cytotoxic chemotherapy. Treatment starts after the appropriate bone and menopausal assessment, and radiotherapy is coordinated with the completed local plan.
- At follow-up she is taking the endocrine treatment, reports manageable symptoms and can explain why the combined clinical and tumour-profile assessment led to this choice. The clinician verifies the monitoring and intolerance plan. A different nodal, hormonal or risk population would require a fresh eligibility assessment rather than copying this outcome.